Patents by Inventor Dietrich Horlein

Dietrich Horlein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • hIL-4 mutant proteins used as antagonists or partial agonists of human interleukin 4
    Patent number: 6130318
    Abstract: The present invention relates to novel hIL-4 mutant proteins, to processes for preparing them, and to their use as medicaments, in particular in overshooting, falsely regulated immune reactions and autoimmune diseases.
    Type: Grant
    Filed: December 19, 1996
    Date of Patent: October 10, 2000
    Assignee: Bayer Aktiengellschaft
    Inventors: Hanno Wild, Rudolf Hanko, Michael Dorschug, Hans-Dietrich Horlein, Jurgen Beunink, Heiner Apeler, Hermann Wehlmann, Walter Sebald
  • Variants of bovine pancreatic trypsin inhibitor produced by recombinant DNA technology, process expression vector and recombinant host therefor and pharmaceutical use thereof
    Patent number: 5770568
    Abstract: Peptides having essentially the sequence of bovine pancreatic trypsin inhibitor (aprotinin) wherein one or more of the amino acids at positions 15, 16, 17, 18, 34, 39 and 52 are replaced by any naturally occurring amino acid produced by recombinant DNA technology, process, expression vector and recominant host therefor and pharmaceutical use thereof. Such peptides being useful as therapeutic agents in diseases connected with the presence of excessive amounts of proteinases.
    Type: Grant
    Filed: January 9, 1995
    Date of Patent: June 23, 1998
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ernst-August Auerswald, Wolfgang Bruns, Dietrich Horlein, Gerd Reinhardt, Eugen Schnabel, Werner Schroder
  • Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
    Patent number: 5231010
    Abstract: An aprotinin with a deletion of the amino acid proline in position 2 or an addition of alanine-(-2)-glutamine-(-1). Such aprotinin is useful as an active ingredient in medicaments.
    Type: Grant
    Filed: June 25, 1992
    Date of Patent: July 27, 1993
    Assignee: Bayer Aktiengesellschaft
    Inventors: Jurgen Ebbers, Dietrich Horlein, Michael Schedel, Rathindra Das
  • Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
    Patent number: 5164482
    Abstract: An aprotinin with a deletion of the amino acid proline in position 2 or an addition of alanine-(-2)- glutamine-(-1). Such aprotinin is useful as an active ingredient in medicaments.
    Type: Grant
    Filed: August 24, 1990
    Date of Patent: November 17, 1992
    Assignee: Bayer Aktiengesellschaft
    Inventors: Jurgen Ebbers, Dietrich Horlein, Michael Schedel, Rathindra Das
  • Variants of bovine pancreatic trypsin inhibitor and pharmaceutical use thereof
    Patent number: 5118668
    Abstract: Peptides having essentially the sequence of bovine pancreatic trypsin inhibitor (aprotinin) wherein one or more of the amino acids at positions 15, 16, 17, 18, 34, 39 and 52 are replaced by any naturally occurring amino acid produced by recombinant DNA technology, process, expression vector and recominant host therefor and pharmaceutical use thereof. Such peptides being useful as therapeutic agents in diseases connected with the presence of excessive amounts of proteinases.
    Type: Grant
    Filed: July 20, 1988
    Date of Patent: June 2, 1992
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ernst-August Auerswald, Wolfgang Bruns, Dietrich Horlein, Gerd Reinhardt, Eugen Schnabel, Werner Schroder